284 related articles for article (PubMed ID: 31252364)
1. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
2. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
3. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
4. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
5. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
6. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
7. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
9. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
10. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
[TBL] [Abstract][Full Text] [Related]
11. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
[TBL] [Abstract][Full Text] [Related]
12. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
Richter S; Wagner B; Celius EG
J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
[No Abstract] [Full Text] [Related]
13. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
[TBL] [Abstract][Full Text] [Related]
15. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
[TBL] [Abstract][Full Text] [Related]
16. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
17. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
18. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
19. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
